Daglozin®-M
Therapeutic Segment:
Anti-diabetic
Generic Name:
Dapagliflozin+Metformin HCI
Description:
Daglozin-M (dapagliflozin and metformin HCl) tablets contain two oral antihyperglycemic medications used in the management of type 2 diabetes: dapagliflozin and metformin hydrochloride.
Indication:
Daglozin-M is indicated in adults aged 18 years-74 years with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:
- In patients inadequately controlled on their maximally tolerated dose of metformin alone
- In combination with other glucose-lowering medicinal products, including insulin, in patients inadequately controlled with metformin and these medicinal products.
- In patients, already being treated with the combination of dapagliflozin and metformin as separate tablets.
Formulation:
- Tablets
Strength:
- 5mg/850mg
- 5mg/1000mg
Pack Size:
- 14’s